US-China Biomedical Technology Inc. said its normalized net income for the fiscal third quarter ended Nov. 30, 2015, came to a loss of $7,790, compared with a loss of $35,640 in the year-earlier period.
Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.
Reported net income came to a loss of $12,460, or a loss of 0 cents per share, compared to a loss of $58,300, or a loss of 6 cents per share, in the year-earlier period.
